Translational Research in Alzheimer's Disease and related Dementias (TRADD)
阿尔茨海默病和相关痴呆症的转化研究 (TRADD)
基本信息
- 批准号:10709167
- 负责人:
- 金额:$ 29.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Project Summary/Abstract
The University of Arizona (UArizona) Training Program to Advance Translational Research on Alzheimer's
Disease and AD Related Dementias (AZ-TRADD) is designed to address knowledge and experience gaps in AD
therapeutic discovery and preclinical translational development. To meet this challenge, the UArizona
Translational Research in AD and related Dementias (AZ-TRADD) training program is designed as a problem
based translational learning experience for predoctoral Ph.D and M.D./Ph.D fellows. In alignment with the 2021
NIH Alzheimer’s Research Summit: Path to Precision Medicine for Treatment and Prevention and the 2011
National Alzheimer’s Project Act (NAPA), the goal of the AZ-TRADD training program is to fill critical gaps that
exist for AD translational research in academic graduate programs. To achieve this goal, the AZ-TRADD program
will: 1) recruit trainees across multiple scientific disciplines; 2) employ problem-based learning approaches to
solve challenges in AD therapeutic development with emerging tools and techniques; and 3) equip AZ-TRADD
trainees with career development and leadership skills necessary to conduct team science and manage
multidisciplinary teams. Through this approach, we ensure that AZ-TRADD trainees develop deep translational
research expertise necessary for AD therapeutic development, while: 1) cultivating the ability to creatively and
collaboratively solve problems working with experts across the translational landscape as part of large-scale
team science; 2) gaining an applied understanding of how data science, particularly using data generated by
AMP-AD, M2OVE-AD and ADNI, can accelerate translational research and provide avenues to novel therapeutic
insights; 3) connecting geno- and phenotypic variations and multifaceted etiology of AD to therapeutic targets;
and 4) gaining essential professional and business skills to navigate a diverse funding landscape and translate
discoveries into the clinical setting. AZ-TRADD fellows will receive career mentoring and leadership development
skills to manage multi-disciplinary teams in the 21st century that is Patient Inspired and Data Driven. The AZ-
TRADD training program will develop a diverse, cross-disciplinary, and translationally oriented workforce to meet
the critical challenge of creating a workforce capable of advancing therapeutics to prevent, delay, and treat AD
and AD related dementias.
项目摘要/摘要
亚利桑那大学(UArizona)促进阿尔茨海默氏症翻译研究的培训计划
疾病和AD相关痴呆(AZ-Tradd)旨在解决AD方面的知识和经验差距
治疗发现和临床前转化发展。为了迎接这一挑战,亚利桑那州大学
AD和相关痴呆的翻译研究(AZ-Tradd)培训计划被设计为一个问题
基于博士前博士和医学博士/博士研究生的翻译学习经验。与2021年保持一致
美国国立卫生研究院阿尔茨海默氏症研究峰会:精准医学治疗和预防之路及2011年
国家阿尔茨海默氏症项目法案(NPA),AZ-Tradd培训计划的目标是填补关键空白,
在学术研究生项目中存在AD翻译研究。为了实现这一目标,AZ-Tradd方案
将:1)招募跨多个科学学科的受训人员;2)采用以问题为基础的学习方法
利用新兴工具和技术解决AD治疗开发中的挑战;以及3)装备AZ-Tradd
具有进行团队科学和管理所需的职业发展和领导技能的受训人员
多学科团队。通过这种方法,我们确保AZ-Tradd实习生发展深度翻译
AD治疗开发所需的研究专业知识,同时:1)培养创造性和
与翻译领域的专家协作解决问题,这是大规模
团队科学;2)获得数据科学的应用理解,特别是使用由
AMP-AD、M20VE-AD和ADNI可以加速翻译研究,并为新的治疗方法提供途径
3)将阿尔茨海默病的基因和表型变异及多方面病因与治疗靶点联系起来;
以及4)获得基本的专业和业务技能,以驾驭多样化的融资环境并进行翻译
在临床环境中的发现。AZ-Tradd研究员将接受职业指导和领导力发展
在21世纪管理多学科团队的技能,这是耐心激励和数据驱动的。亚洲区-
贸易培训计划将培养一支多元化、跨学科、以翻译为导向的劳动力队伍,以满足
创建一支能够推进预防、延迟和治疗AD的治疗方法的员工队伍的关键挑战
以及与AD相关的痴呆。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERTA EILEEN BRINTON其他文献
ROBERTA EILEEN BRINTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERTA EILEEN BRINTON', 18)}}的其他基金
Novel Intranasal Formulations of Allopregnanolone, a Regenerative Therapeutic for Alzheimer's Disease
Allopregnanolone 的新型鼻内制剂,一种阿尔茨海默病的再生疗法
- 批准号:
10698555 - 财政年份:2023
- 资助金额:
$ 29.45万 - 项目类别:
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
PhytoSERM 预防更年期相关脑代谢和认知能力下降的功效:双盲、随机、安慰剂对照 2 期临床试验
- 批准号:
10560591 - 财政年份:2022
- 资助金额:
$ 29.45万 - 项目类别:
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
PhytoSERM 针对更年期潮热和持续大脑健康
- 批准号:
10547639 - 财政年份:2022
- 资助金额:
$ 29.45万 - 项目类别:
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
PhytoSERM 预防更年期相关脑代谢和认知能力下降的功效:双盲、随机、安慰剂对照 2 期临床试验
- 批准号:
10344556 - 财政年份:2022
- 资助金额:
$ 29.45万 - 项目类别:
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
PhytoSERM 针对更年期潮热和持续大脑健康
- 批准号:
10707107 - 财政年份:2022
- 资助金额:
$ 29.45万 - 项目类别:
Regulatory and Human Study Operations (RHSO) Core C
监管和人体研究运营 (RHSO) 核心 C
- 批准号:
10689308 - 财政年份:2021
- 资助金额:
$ 29.45万 - 项目类别:
Regulatory and Human Study Operations (RHSO) Core C
监管和人体研究运营 (RHSO) 核心 C
- 批准号:
10491851 - 财政年份:2021
- 资助金额:
$ 29.45万 - 项目类别:
Regulatory and Human Study Operations (RHSO) Core C
监管和人体研究运营 (RHSO) 核心 C
- 批准号:
10270190 - 财政年份:2021
- 资助金额:
$ 29.45万 - 项目类别:
Undergraduate Readying for Burgeoning Research for American Indian Neuroscientists
本科生为美洲印第安人神经科学家的新兴研究做好准备
- 批准号:
10199069 - 财政年份:2019
- 资助金额:
$ 29.45万 - 项目类别: